OncoMatch/Clinical Trials/NCT05651178
Human CD19-CD22 Targeted T Cells Injection for Refractory/Relapsed Central Nervous System Leukemia/Lymphoma Patients
Is NCT05651178 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies Human CD19-CD22 Targeted T Cells for central nervous system lymphoma.
Treatment: Human CD19-CD22 Targeted T Cells — This study is a open-label, dose-escalation trial to explore the safety, tolerability and pharmacokinetic/pharmacodynamics characteristics of Human CD19-CD22 Targeted T Cells by intravenous and intrathecal administration, and to preliminarily observe the efficacy of the trial drug in patients with central nervous system involvement of refractory/relapsed B cell malignancies.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD19 positive (positive)
Required: CD22 positive (positive)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: CAR-T cell therapy
Received CAR-T treatment or other gene therapies before enrollment
Cannot have received: gene therapy
Received CAR-T treatment or other gene therapies before enrollment
Lab requirements
Kidney function
creatinine within the normal range
Liver function
total bilirubin ≤ 2×uln; alt and ast ≤ 2.5×uln
Cardiac function
left ventricular ejection fraction > 50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify